Ratings Canopy Growth Corporation

Equities

WEED

CA1380357048

Market Closed - Toronto S.E. Other stock markets 21:00:00 13/09/2024 BST			5-day change	1st Jan Change
6.510 ^CAD	+1.24%		+7.25%	-3.70%

08-27	Health Care Flat as Cannabis Shares Slide -- Health Care Roundup	DJ
08-27	Pot stocks fall as US DEA pushes cannabis reclassification hearing to December	RE

Summary: Canopy Growth Corporation

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Highlights: Canopy Growth Corporation

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses: Canopy Growth Corporation

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's enterprise value to sales, at 3.78 times its current sales, is high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings Chart: Canopy Growth Corporation

Source: Surperformance

ESG chart: Canopy Growth Corporation

Source: Refinitiv

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
CANOPY GROWTH CORPORATION	-	403M
DONG-E-E-JIAO CO.,LTD.		4.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.		3.49B
TASLY PHARMACEUTICAL GROUP CO., LTD		2.85B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-	2.54B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.		1.49B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-	1.35B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK		1.31B
Average		2.19B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

C-

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes